摘要
目的:探讨都梁软胶囊联合阿罗洛尔防治偏头痛的疗效。方法:将101例临床确诊为偏头痛的患者以随机抽样法分为2组,都梁软胶囊联合阿罗洛尔组(观察组)51例,阿罗洛尔组(对照组)50例。观察组给予都梁软胶囊1次3粒,1日3次,口服;阿罗洛尔10 mg,1日1次,口服。对照组给予阿罗洛尔10 mg,1日1次,口服。2组患者均连续治疗12周,并随访3个月,比较2组患者治疗前后头痛发作频次、严重程度、持续时间以及不良反应情况。结果:观察组患者头痛发作频次、严重程度和持续时间均明显减少,与对照组比较差异有统计学意义(P<0.05),且不良反应少。结论:都梁软胶囊联合阿罗洛尔可改善慢性偏头痛患者的头痛发作程度,减少头痛的持续时间,值得临床推广应用。
OBJECTIVE：To evaluate the efficacy of Duliang soft capsules in combination with Arotinolol in theprevention and treatment of migraine. METHODS： Patients diagnosed as having migraine were randomly assigned to receive Duliang soft capsules （ one capsule/time t. i. d orally） in combination with Arotinolol （ 10 mg q. d orally） （observation group） or Arotinolol （10 mg q. d orally） alone （control group） for 12 weeks. The patients were followed- up for 3 months, with the two groups compared with regard to frequency, severity and duration of migraine attack and adverse drug reactions before and after treatment. RESULTS： The frequency, severity and duration of migraine attack were significantly reduced in the observation group, showing statistically control group （ P 〈 0.05 ）. CONCLUSION ： Duliang soft capsules in severity and duration of the attack of chronic migraine hence the therapy significant differences as compared with the combination with Arotinolol can reduce the is worthy of clinical popularization.
出处
《中国医院用药评价与分析》
2013年第4期365-367,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
慢性偏头痛
都梁软胶囊
阿罗洛尔
Chronic migraine
Duliang soft capsules
Arotinolol
